nanotech investing Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
nanotech investing Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
nanotech investing Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
nanotech investing Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
nanotech investing Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
nanotech investing Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
nanotech investing Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
nanotech investing Nuvation Bio Announces IBTROZI® Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
nanotech investing Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
nanotech investing Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
LaFleur Minerals and Trafigura Progress Toward Definitive Agreement, Beacon Gold Mill Nearing Gold Production Restart
